Last C$145.21 CAD
Change Today +1.32 / 0.92%
Volume 623.7K
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Frankfurt
As of 4:00 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Open
C$144.05
Previous Close
C$143.89
Day High
C$145.70
Day Low
C$142.74
52 Week High
02/27/14 - C$170.47
52 Week Low
10/31/13 - C$104.94
Market Cap
48.7B
Average Volume 10 Days
1.1M
EPS TTM
C$3.17
Shares Outstanding
335.7M
EX-Date
11/10/10
P/E TM
40.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (VRX)

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

17,200 Employees
Last Reported Date: 02/28/14
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.8M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0M
Chief Legal Officer, Head of Corporate & Busi...
Total Annual Compensation: $750.0K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $511.1K
Consultant
Total Annual Compensation: $37.9K
Compensation as of Fiscal Year 2013.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International, Inc. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for the Fourth Quarter, Full Year of 2014 and Fiscal 2015

Valeant Pharmaceuticals International, Inc. reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net income of $276.4 million, net income attributable to the company was $275.4 million or $0.82 per basic share and $0.81 per diluted share on total Revenue was $2,056.2 million against net loss of $971.9 million, net loss attributable to the company was $973.2 million or $2.92 per basic and diluted share on total Revenue was $1,541.7 million a year ago. Operating income was $683.9 million and income before provision for income taxes was $376.7 million against operating loss was $891.5 million and loss before recovery of income taxes was $1,141.1 million a year ago. Adjusted net income attributable to the company was $718.8 million compared to $485.9 million a year ago. For the nine months, the company reported net income of $378.1 million, net income attributable to the company was $378.6 million or $1.13 per basic share and $1.11 per diluted share on total Revenue was $5,983.5 million against net loss of $988.6 million, net loss attributable to the company was $989.9 million or $3.13 per basic and diluted share on total Revenue was $3,705.8 million a year ago. Operating income was $1,395.6 million and income before provision for income taxes was $502.5 million against operating loss was $633.0 million and loss before recovery of income taxes was $1,236.3 million a year ago. Adjusted net income attributable to the company was $1,969.1 million compared to $1,311.6 million a year ago. 2014 Guidance for cash EPS updated to $8.22 to $8.32 to reflect third quarter outperformance and stronger expected fourth quarter financial results. Fourth quarter cash EPS raised to $2.45 to $2.55, expect double-digit same store organic growth in the fourth quarter. 2015 Outlook raised to 10%+ Organic Growth and $10.00 cash EPS, assuming no acquisitions.

Shire Is In Merger Talks With NPS

Shire plc (LSE:SHP) is considering another round of talks about a possible merger with NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP) after proposed merger of AbbVie Inc. (NYSE:ABBV) is cancelled. NPS Pharmaceuticals and Cubist Pharmaceuticals (CBST) are the two most likely merger partners for Shire plc, according to reports. Another would be merger partner is Allergan Inc. (NYSE:AGN), with the Paulson & Co. hedge fund voicing support for a deal, according to the Wall Street Journal. Allergan Inc. (NYSE:AGN) is also being pursued by Valeant Pharmaceuticals International, Inc. (TSX:VRX), but has so far rejected its entreaties. NPSP were up about 8.5% at $28.38, SHP about 3.2% at $184.93. CBST shares were up about 1.8% at $67.13.

Valeant Pharmaceuticals International, Inc., Q3 2014 Earnings Call, Oct 20, 2014

Valeant Pharmaceuticals International, Inc., Q3 2014 Earnings Call, Oct 20, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$145.21 CAD +1.32

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $240.33 USD +3.12
Astellas Pharma Inc ¥1,598 JPY +20.50
Mylan Inc/PA $51.22 USD +0.79
Shire PLC 4,050 GBp +155.00
Sun Pharmaceutical Industries Ltd 810.05 INR 0.00
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 87.4x
Price/Sales 5.4x
Price/Book 8.2x
Price/Cash Flow 32.6x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.